New treatments for age-related macular degeneration.
Hamilton
Wanda S
WS
D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D001766:Blindness / Q000517:prevention & control*; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy*; D012952:Societies / Q000458:organization & administration*
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab